1088 related articles for article (PubMed ID: 27617201)
1. Non-alcoholic fatty liver and the gut microbiota.
Bashiardes S; Shapiro H; Rozin S; Shibolet O; Elinav E
Mol Metab; 2016 Sep; 5(9):782-94. PubMed ID: 27617201
[TBL] [Abstract][Full Text] [Related]
2. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiome and nonalcoholic fatty liver diseases.
Zhu L; Baker RD; Baker SS
Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
[TBL] [Abstract][Full Text] [Related]
4. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
[TBL] [Abstract][Full Text] [Related]
5. Intestinal microbiota and nonalcoholic steatohepatitis.
Brandl K; Schnabl B
Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
[TBL] [Abstract][Full Text] [Related]
6. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
Chu H; Williams B; Schnabl B
Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
[TBL] [Abstract][Full Text] [Related]
8. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
[TBL] [Abstract][Full Text] [Related]
9. [Microbiome & NASH - partners in crime driving progression of fatty liver disease].
Wree A; Geisler LJ; Tacke F
Z Gastroenterol; 2019 Jul; 57(7):871-882. PubMed ID: 31288283
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Buffet C
Bull Acad Natl Med; 2014 Dec; 198(9):1641-52. PubMed ID: 27356366
[TBL] [Abstract][Full Text] [Related]
11. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
12. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
Song Q; Zhang X
Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
[TBL] [Abstract][Full Text] [Related]
13. Diet and gut microbiome in fatty liver and its associated liver cancer.
Pan Y; Zhang X
J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
[TBL] [Abstract][Full Text] [Related]
14. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
Chu H; Duan Y; Yang L; Schnabl B
Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
[TBL] [Abstract][Full Text] [Related]
15. Gut Dysfunction and Non-alcoholic Fatty Liver Disease.
Grabherr F; Grander C; Effenberger M; Adolph TE; Tilg H
Front Endocrinol (Lausanne); 2019; 10():611. PubMed ID: 31555219
[TBL] [Abstract][Full Text] [Related]
16. The role of the microbiome in NAFLD and NASH.
Kolodziejczyk AA; Zheng D; Shibolet O; Elinav E
EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30591521
[TBL] [Abstract][Full Text] [Related]
17. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.
Panasevich MR; Peppler WT; Oerther DB; Wright DC; Rector RS
Physiol Genomics; 2017 Aug; 49(8):385-399. PubMed ID: 28600319
[TBL] [Abstract][Full Text] [Related]
18. Roles of Traditional and Next-Generation Probiotics on Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Network Meta-Analysis.
Zhu Y; Tan JK; Liu J; Goon JA
Antioxidants (Basel); 2024 Mar; 13(3):. PubMed ID: 38539862
[TBL] [Abstract][Full Text] [Related]
19. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Kirpich IA; Marsano LS; McClain CJ
Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
[TBL] [Abstract][Full Text] [Related]
20. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of
Wang T; Ishikawa T; Sasaki M; Chiba T
Front Med (Lausanne); 2022; 9():822190. PubMed ID: 35308549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
